FDA approves antiplatelet drug for use during PCI
On June 22, the U.S. Food and Drug Administration (FDA) approved Kengreal (cangrelor), an I.V. antiplatelet drug, for use in adults undergoing undergoing percutaneous…
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.